1. Home
  2. MMI vs CRVS Comparison

MMI vs CRVS Comparison

Compare MMI & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MMI

Marcus & Millichap Inc.

HOLD

Current Price

$30.71

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$15.60

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MMI
CRVS
Founded
1971
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
2013
2016

Fundamental Metrics

Financial Performance
Metric
MMI
CRVS
Price
$30.71
$15.60
Analyst Decision
Sell
Strong Buy
Analyst Count
2
6
Target Price
$28.00
$30.17
AVG Volume (30 Days)
179.5K
1.4M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
1.78%
N/A
EPS Growth
84.38
48.04
EPS
N/A
N/A
Revenue
$719,700,000.00
N/A
Revenue This Year
$14.04
N/A
Revenue Next Year
$11.35
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$24.43
$3.96
52 Week High
$33.62
$26.95

Technical Indicators

Market Signals
Indicator
MMI
CRVS
Relative Strength Index (RSI) 52.84 67.46
Support Level $28.50 $14.24
Resistance Level $30.86 $16.85
Average True Range (ATR) 0.75 0.81
MACD -0.03 0.33
Stochastic Oscillator 50.26 80.50

Price Performance

Historical Comparison
MMI
CRVS

About MMI Marcus & Millichap Inc.

Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans. The Company has one reportable segment: commercial real estate services. The commercial real estate services segment is the aggregation of our two operating segments: investment sales and financing services.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Share on Social Networks: